245 completed, 55 unknown, 30 recruiting, 24 terminated. 122 Phase 4, 74 Phase 3, 70 Phase 2, 60 Not applicable, 42 Phase 1.
Follow Methylphenidate: new trials by email Literature Review of Methylphenidate trials Research Report on Methylphenidate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder Delayed-release, extended-release methylphenidate, Placebo - ADHD, Cannabis Use Disorder | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 66 | 2026-11-01 | 2026-09-28 |
| Methylphenidate and Response to Alcohol Cues Methylphenidate Pill, Placebo Pill - Alcohol Use Disorder | Phase 2 | Not yet recruiting | University of Florida | 50 | 2026-10-01 | 2026-08-20 |
| A Multimodal Imaging Study of Dopamine in Early Psychosis Methylphenidate (MPH), [11C]raclopride - Clinical High Risk for Psychosis (CHR) | Phase 1 | Not yet recruiting | New York State Psychiatric Institute | 115 | 2026-10-01 | 2026-07-14 |
| EEG Biomarkers for ADHD Stimulant Treatment methylphenidate HCl, Mixed amphetamine salts extended release - ADHD | Phase 4 | Not yet recruiting | Boston Children's Hospital | 220 | 2026-09-15 | 2026-06-16 |
| The Efficacy of a Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD methylphenidate (Ritalin®), Reboxetine, Placebo - PTSD, Posttraumatic Stress Disorder | Phase 2 | Recruiting | University of Haifa | 160 | 2026-08-01 | 2026-08-18 |
| Medication Treatment of ADHD in Pediatric Epilepsy methylphenidate hydrochloride (Jornay PM) - ADHD - Attention Deficit Disorder With Hyperactivity | Phase 4 | Recruiting | Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | 25 | 2026-05-29 | 2026-07-29 |
| Treating Young Children With Attention Deficit Hyperactivity Disorder Guanfacine (GUA), Methylphenidate (MPH) - Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 370 | 2026-02-16 | 2026-09-14 |
| A Trial to Assess How Centanafadine Interacts With Stimulants in the Body Centanafadine, Methylphenidate, Lisdexamfetamine - ADHD | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 40 | 2026-02-05 | 2026-05-05 |
| Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial 3,4-Methylenedioxymethamphetamine, Methylphenidate - Chronic Neuropathic Pain | Phase 2 | Recruiting | Unity Health Toronto | 50 | 2026-01-30 | 2026-07-29 |
| Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia intermittent theta burst stimulation (iTBS), Methylphenidate (MPH) - Alzheimer s Disease, Alzheimer Dementia (AD) | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 12 | 2026-01-01 | 2025-12-12 |
| Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue Methylphenidate (MPH), Placebo - Brain Tumor, Pediatric, Cancer-related Fatigue | Phase 3 | Recruiting | Odense University Hospital | 50 | 2025-09-02 | 2026-06-26 |
| An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening Methylphenidate Hydrochloride Extended Release Capsule - Attention-deficit/Hyperactivity Disorder | Phase 4 | Recruiting | NYU Langone Health | 30 | 2025-01-29 | 2026-04-29 |
| The Effects of Methylphenidate on Symptomatology in Individuals With Borderline Personality Disorder methylphenidate, matched placebo tablet - Borderline Personality Disorder | Early Phase 1 | Not yet recruiting | Tanta University | 60 | 2025-01-15 | 2025-01-06 |
| Methylphenidate in KBG Syndrome: N-of-1 Series Methylphenidate Hydrochloride, Placebo - Kbg Syndrome, ADHD - Combined Type | Phase 4 | Recruiting | Radboud University Medical Center | 15 | 2024-11-13 | 2026-08-11 |
| Precision Care for Major Depressive Disorder Pramipexole, Methylphenidate, Phenelzine - Major Depressive Disorder, Depression | Phase 4 | Enrolling by invitation | University of California, San Francisco | 150 | 2024-11-12 | 2025-09-05 |
| Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD HLD200 methylphenidate hydrochloride capsules, Placebo HLD200 capsules - Attention Deficit Hyperactivity Disorder | Phase 3 | Terminated | Ironshore Pharmaceuticals and Development, Inc | 26 | 2024-09-13 | 2025-11-06 |
| The Effect of Methylphenidate Treatment on Oxidative Stress Levels in Children Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD) This is not an interventional study. Patients who are planned to start methylphenidate treatment have been invited to participate in the study. - Attention Deficit Hyperactivity Disorder (ADHD) | Completed | Saglik Bilimleri Universitesi | 39 | 2024-06-26 | 2025-06-08 | |
| Psilocybin in Chronic Low Back Pain and Depression Psilocybin, Methylphenidate - Chronic Low-back Pain, Depression | Phase 1 | Recruiting | Johns Hopkins University | 40 | 2024-04-22 | 2026-09-04 |
| Multimodal Brain Imaging of Methylphenidate in Children and Adolescents With ADHD Methylphenidate, Placebo - ADHD | Phase 4 | Withdrawn | Johns Hopkins University | 2024-04-16 | 2024-03-15 | |
| Methylphenidate and Response to Alcohol Cues Pilot Study Methylphenidate Pill - Alcohol Use Disorder, Attention Deficit Hyperactivity Disorder | Early Phase 1 | Completed | University of Florida | 31 | 2024-03-20 | 2026-02-10 |
Showing 20 of 382. Sign in to see all of them.
Attention Deficit Disorder with Hyperactivity (216) · Fatigue (19) · Lethargy (11) · Cocaine-Related Disorders (10) · Substance-Related Disorders (10) · Alzheimer Disease (9) · Dementia (8) · Depression (8) · Neoplasms (8) · Brain Injuries, Traumatic (7) · Parkinson Disease (7) · Cognitive Dysfunction (6) · Stress Disorders, Post-Traumatic (6) · Autistic Disorder (5) · Brain Neoplasms (5)
Massachusetts General Hospital (22) · M.D. Anderson Cancer Center (10) · Children's Hospital Medical Center, Cincinnati (7) · National Institute on Drug Abuse (NIDA) (7) · New York State Psychiatric Institute (7) · Shalvata Mental Health Center (7) · Icahn School of Medicine at Mount Sinai (6) · Shire (6) · University of Cincinnati (6) · Florida International University (5) · Ironshore Pharmaceuticals and Development, Inc (5) · Johns Hopkins University (5) · Noven Therapeutics (5) · Alza Corporation, DE, USA (4) · National Institute of Mental Health (NIMH) (4)
United States (202) · Israel (28) · Canada (27) · Germany (14) · France (12) · Netherlands (12) · Sweden (9) · Switzerland (9) · South Korea (8) · Denmark (7) · Taiwan (7) · Belgium (6) · Brazil (6) · Norway (5) · United Kingdom (5)
Joseph Biederman, MD (5) · Lily Hechtman, MD, FRCPC (4) · Thomas Spencer, MD (4) · Jeffrey Newcorn, MD (3) · Timothy Wilens, MD (3) · Ann Childress, MD (2) · Avi Avital, PhD (2) · Chandra Sekhar Sripada, MD, PhD (2) · Craig Surman, MD (2) · Eduardo Bruera, MD (2)
PMID 35201607, PMID 36971690, PMID 41342306, PMID 10385840, PMID 14595084, PMID 24290461, PMID 26745211, PMID 27082828, PMID 28980198, PMID 29912955, PMID 37811711, PMID 10560028, PMID 10662747, PMID 10990547, PMID 11389303, PMID 11514638, PMID 11581440, PMID 11864719, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12139997, PMID 12578439, PMID 12832331, PMID 13539317, PMID 14199369, PMID 14675812, PMID 15066944, PMID 15076258, PMID 1537959, PMID 15381021, PMID 15710782, PMID 15738343, PMID 15753425, PMID 15827573, PMID 15869352, PMID 15910203, PMID 15934489, PMID 15950006, PMID 15950016, PMID 15969353, PMID 16041867, PMID 16102908, PMID 16175106, PMID 16262992, PMID 16275814, PMID 16389216, PMID 16429090, PMID 16671928, PMID 16680409
2008 (3), 2014 (3), U10CA081920 (2), 1RC2DA028905-01 (1), 2015 (1), 2016 (1), 2023 (1), DP2HD101400 (1), IK2CX002104 (1), K12DA000357 (1), K23MH064975 (1), K23MH066835 (1), K23MH083881 (1), M01RR010710 (1), P30CA021765 (1)